A xylogalactofucan from the brown seaweed Spatoglossum schröederi stimulates the synthesis of an antithrombotic heparan sulfate from endothelial cells.
The brown seaweed Spatoglossum schröederi (Dictyotaceae) contains three main fucans (fucans A, B and C) with different mobility in electrophoresis. The fucan with highest mobility (fucan C) was precipitated with 2.0 volumes of acetone, purified using a combination of ion exchange chromatography and electrophoresis. It showed an MW of 24 kDa determined by HPLC and Sephadex G-75 chromatography and migrates as a single band in three distinct electrophoretic systems. This fucan contains fucose, xylose, galactose and sulfate in a molar ratio 1 : 0.6 : 2:2.3. The fucan has neither anticoagulant (from 10 to 100 microg) nor hemorrhagic activities (100 microg/mL). In addition, fucan C is neither cytotoxic nor cytostatic. However, fucan C (100 microg/mL) stimulated the synthesis of an antithrombotic heparan sulfate from endothelial cells of rabbit aorta. The results suggest that fucan C might be used as an antithrombotic therapeutic compound.
Rocha
Hugo Alexandre de Oliveira
HA
Laboratório de Glicobiologia, Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Rio Grande do Norte-UFRN, Natal-RN, Brazil. hugo-alexandre@uol.com.br
Bezerra
Luana Cristina Lins de Medeiros
LC
de Albuquerque
Ivan Rui Lopes
IR
Costa
Leandro Silva
LS
Guerra
Celina Maria Pinto
CM
de Abreu
Luiz Diz
LD
Nader
Helena Bonciani
HB
Leite
Edda Lisboa
EL
D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006497:Heparan Sulfate / Q000096:biosynthesis*; D006801:Humans; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012624:Seaweed; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D006497:Heparan Sulfate; D010936:Plant Extracts; D013917:Thrombin